Summary
- FDA is reportedly shunning advisory committees.
- Concerns from drugmakers, patients, and doctors.
- Potential implications for drug approval processes.
Key Facts
| Fact | Value |
|---|---|
| Source | STAT |
| Published Date | March 9, 2026 |
Strategic angle: Growing worries about the FDA's diminishing use of advisory committees for public discourse.
| Fact | Value |
|---|---|
| Source | STAT |
| Published Date | March 9, 2026 |